Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients

Barbara S Van der Meij; Laisa Teleni; Avalyn E. Stanislaus; Rachel A. Murphy; Lindsay Robinson; Vijaya L. Damaraju; Quincy Chu; Michael B. Sawyer; Vera  Mazurak

doi:10.1016/j.clnesp.2020.09.009

Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients

Barbara S Van der Meij
, Laisa Teleni
, Avalyn E. Stanislaus
, Rachel A. Murphy
, Lindsay Robinson
, Vijaya L. Damaraju
, Quincy Chu
, Michael B. Sawyer
, Vera Mazurak

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

319 Downloads (Pure)

Abstract

Background & aims
Pre-clinical studies suggest that 16:4(n-3) in purified form or as a component of fish oil might induce platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 16:4(n-3) before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients supplemented with fish oil or provided standard care, and to explore relationships between plasma 16:4(n-3) levels and tumor response to treatment.

Methods
In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC (n = 21) who underwent platinum-based chemotherapy and were assigned to 2.2 g/day of eicosapentaenoic (EPA) plus 1.1 g DHA/day as fish oil (FO; n = 12) or received no intervention (standard care; SC; n = 9). Plasma 16:4(n-3) was quantified as free and esterified (total) fatty acid using HPLC-MS/MS. Plasma 16:4(n-3) levels were evaluated over time in relation to fish oil supplementation and response to platinum-based therapy, and compared with a group of healthy subjects (REF; n = 11).

Results
Plasma 16:4(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 16:4(n-3) was higher for FO versus SC group (2.7 versus −1.8%/d, U = 20, p = 0.02), but change in plasma free 16:4(n-3) was not different between FO and SC. Median plasma free and esterified 16:4(n-3) were similar between responders and non-responders to platinum-based chemotherapy. Total and free plasma 16:4(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC vs REF: total 16:4(n-3): 122.9 vs. 95.2 nM and free 16:4(n-3) 23.9 vs. 27.6 nM).

Conclusions
This first of its kind study that evaluated plasma 16:4(n-3) in NSCLC patients showed that 16:4 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy.

Original language	English
Pages (from-to)	263-268
Number of pages	6
Journal	Clinical Nutrition ESPEN
Volume	40
Early online date	7 Oct 2020
DOIs	https://doi.org/10.1016/j.clnesp.2020.09.009
Publication status	Published - Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.clnesp.2020.09.009

Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patientsAccepted author manuscript, 599 KBLicence: CC BY-NC-ND

Cite this

Van der Meij, B. S., Teleni, L., Stanislaus, A. E., Murphy, R. A., Robinson, L., Damaraju, V. L., Chu, Q., Sawyer, M. B., & Mazurak, V. (2020). Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients. Clinical Nutrition ESPEN, 40, 263-268. https://doi.org/10.1016/j.clnesp.2020.09.009

@article{330f40ddc6a84c498c133af4f7fe0e5d,

title = "Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients",

abstract = "Background \& aims Pre-clinical studies suggest that 16:4(n-3) in purified form or as a component of fish oil might induce platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 16:4(n-3) before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients supplemented with fish oil or provided standard care, and to explore relationships between plasma 16:4(n-3) levels and tumor response to treatment. Methods In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC (n = 21) who underwent platinum-based chemotherapy and were assigned to 2.2 g/day of eicosapentaenoic (EPA) plus 1.1 g DHA/day as fish oil (FO; n = 12) or received no intervention (standard care; SC; n = 9). Plasma 16:4(n-3) was quantified as free and esterified (total) fatty acid using HPLC-MS/MS. Plasma 16:4(n-3) levels were evaluated over time in relation to fish oil supplementation and response to platinum-based therapy, and compared with a group of healthy subjects (REF; n = 11). Results Plasma 16:4(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 16:4(n-3) was higher for FO versus SC group (2.7 versus −1.8\%/d, U = 20, p = 0.02), but change in plasma free 16:4(n-3) was not different between FO and SC. Median plasma free and esterified 16:4(n-3) were similar between responders and non-responders to platinum-based chemotherapy. Total and free plasma 16:4(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC vs REF: total 16:4(n-3): 122.9 vs. 95.2 nM and free 16:4(n-3) 23.9 vs. 27.6 nM). Conclusions This first of its kind study that evaluated plasma 16:4(n-3) in NSCLC patients showed that 16:4 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy.",

author = "\{Van der Meij\}, \{Barbara S\} and Laisa Teleni and Stanislaus, \{Avalyn E.\} and Murphy, \{Rachel A.\} and Lindsay Robinson and Damaraju, \{Vijaya L.\} and Quincy Chu and Sawyer, \{Michael B.\} and Vera Mazurak",

year = "2020",

month = dec,

doi = "10.1016/j.clnesp.2020.09.009",

language = "English",

volume = "40",

pages = "263--268",

journal = "Clinical Nutrition ESPEN",

issn = "2405-4577",

publisher = "Elsevier",

}

Van der Meij, BS, Teleni, L, Stanislaus, AE, Murphy, RA, Robinson, L, Damaraju, VL, Chu, Q, Sawyer, MB & Mazurak, V 2020, 'Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients', Clinical Nutrition ESPEN, vol. 40, pp. 263-268. https://doi.org/10.1016/j.clnesp.2020.09.009

Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients. / Van der Meij, Barbara S; Teleni, Laisa; Stanislaus, Avalyn E. et al.
In: Clinical Nutrition ESPEN, Vol. 40, 12.2020, p. 263-268.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients

AU - Van der Meij, Barbara S

AU - Teleni, Laisa

AU - Stanislaus, Avalyn E.

AU - Murphy, Rachel A.

AU - Robinson, Lindsay

AU - Damaraju, Vijaya L.

AU - Chu, Quincy

AU - Sawyer, Michael B.

AU - Mazurak, Vera

PY - 2020/12

Y1 - 2020/12

N2 - Background & aims Pre-clinical studies suggest that 16:4(n-3) in purified form or as a component of fish oil might induce platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 16:4(n-3) before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients supplemented with fish oil or provided standard care, and to explore relationships between plasma 16:4(n-3) levels and tumor response to treatment. Methods In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC (n = 21) who underwent platinum-based chemotherapy and were assigned to 2.2 g/day of eicosapentaenoic (EPA) plus 1.1 g DHA/day as fish oil (FO; n = 12) or received no intervention (standard care; SC; n = 9). Plasma 16:4(n-3) was quantified as free and esterified (total) fatty acid using HPLC-MS/MS. Plasma 16:4(n-3) levels were evaluated over time in relation to fish oil supplementation and response to platinum-based therapy, and compared with a group of healthy subjects (REF; n = 11). Results Plasma 16:4(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 16:4(n-3) was higher for FO versus SC group (2.7 versus −1.8%/d, U = 20, p = 0.02), but change in plasma free 16:4(n-3) was not different between FO and SC. Median plasma free and esterified 16:4(n-3) were similar between responders and non-responders to platinum-based chemotherapy. Total and free plasma 16:4(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC vs REF: total 16:4(n-3): 122.9 vs. 95.2 nM and free 16:4(n-3) 23.9 vs. 27.6 nM). Conclusions This first of its kind study that evaluated plasma 16:4(n-3) in NSCLC patients showed that 16:4 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy.

AB - Background & aims Pre-clinical studies suggest that 16:4(n-3) in purified form or as a component of fish oil might induce platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 16:4(n-3) before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients supplemented with fish oil or provided standard care, and to explore relationships between plasma 16:4(n-3) levels and tumor response to treatment. Methods In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC (n = 21) who underwent platinum-based chemotherapy and were assigned to 2.2 g/day of eicosapentaenoic (EPA) plus 1.1 g DHA/day as fish oil (FO; n = 12) or received no intervention (standard care; SC; n = 9). Plasma 16:4(n-3) was quantified as free and esterified (total) fatty acid using HPLC-MS/MS. Plasma 16:4(n-3) levels were evaluated over time in relation to fish oil supplementation and response to platinum-based therapy, and compared with a group of healthy subjects (REF; n = 11). Results Plasma 16:4(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 16:4(n-3) was higher for FO versus SC group (2.7 versus −1.8%/d, U = 20, p = 0.02), but change in plasma free 16:4(n-3) was not different between FO and SC. Median plasma free and esterified 16:4(n-3) were similar between responders and non-responders to platinum-based chemotherapy. Total and free plasma 16:4(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC vs REF: total 16:4(n-3): 122.9 vs. 95.2 nM and free 16:4(n-3) 23.9 vs. 27.6 nM). Conclusions This first of its kind study that evaluated plasma 16:4(n-3) in NSCLC patients showed that 16:4 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy.

UR - https://www.scopus.com/pages/publications/85092238846

U2 - 10.1016/j.clnesp.2020.09.009

DO - 10.1016/j.clnesp.2020.09.009

M3 - Article

C2 - 33183547

SN - 2405-4577

VL - 40

SP - 263

EP - 268

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

ER -

Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Oncology Nutrition Research

Cite this

Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Related Projects

Oncology Nutrition Research

Cite this